ACRS
Aclaris Therapeutics Inc
NASDAQ: ACRS · HEALTHCARE · BIOTECHNOLOGY
$4.47
+5.92% today
Updated 2026-04-29
Market cap
$624.30M
P/E ratio
—
P/S ratio
79.77x
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$1 – $5
Volume
2.0M
Aclaris Therapeutics Inc (ACRS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-1,725.00%
ROE
-50.20%
ROA
-24.30%
Debt/equity
0.02x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | — | $-5.24M | — | — | — |
| 2014 | $0.00 | $-8.52M | — | — | — |
| 2015 | $0.00 | $-20.56M | — | — | — |
| 2016 | $0.00 | $-48.08M | — | — | — |
| 2017 | $1.68M | $-68.52M | 28.28% | -4,303.21% | -4,071.48% |
| 2018 | $10.09M | $-132.74M | 32.12% | -1,341.93% | -1,315.41% |
| 2019 | $4.23M | $-161.35M | 4.07% | -2,627.35% | -3,817.22% |
| 2020 | $6.48M | $-51.15M | 20.81% | -785.44% | -789.17% |
| 2021 | $6.76M | $-90.86M | 30.29% | -1,327.07% | -1,343.96% |
| 2022 | $29.75M | $-86.91M | 59.80% | -302.01% | -292.11% |
| 2023 | $31.25M | $-88.48M | 42.14% | -311.55% | -283.15% |
| 2024 | $18.72M | $-132.06M | 85.09% | -758.18% | -705.48% |
| 2025 | $7.83M | $-64.92M | 73.28% | -975.91% | -829.58% |